Compare Vanguard Value Index Fund ETF (VTV) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Value Index Fund ETF vs Zoetis Inc — how do they compare? Vanguard Value Index Fund ETF trades at $226.59, while Zoetis Inc trades at $73.85 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while Vanguard Value Index Fund ETF pays none, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| VTV | ZTS | |
|---|---|---|
52-Week High | $225.35 | $156.76 |
52-Week Low | $179.43 | $71.91 |
Market Cap | — | $31.14B |
Sector | — | Health |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vanguard Value ETF (VTV) trades at $226.29, up 0.56% today, with a bullish technical signal from moving averages. The ETF focuses on large-cap U.S. value stocks and is benefiting from a rotation into value strategies in 2026, with one Vanguard deep-value fund reportedly up 22% this year. Recent institutional activity shows mixed positioning, with some firms increasing stakes while others reduce holdings.
The outlook for VTV is positive amid the shift toward value investing, though the RSI-6 at 90.75 indicates potential overbought conditions. Risks include market volatility and sector concentration, but its diversified value approach offers stability if growth stocks underperform. Analyst sentiment remains constructive on value ETFs for income and defensive positioning.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
